Unibest
← Back to patent-cliff list

ivaltinostat

Tier C — Watch / trade

ivaltinostat

Crystalgenomics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets:HDAC

Indications (approved):Pancreatic cancer, Myelodysplastic syndrome, Solid tumour, Fibrosis, Haematological malignancy

Regional status

US
Phase II
2022-08-15
EU
-
China
-
Japan
-

Synthetic routes & intermediates1 routes

Originator routes × 1Optimised (non-patent) × 0Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 10 · Total yield 142 mg (CG-200745)
CG-200745-001502-44-3CG-200745-0024547-43-7CG-200745-0036654-36-0CG-200745-004936221-70-4CG-200745-005936221-71-5CG-200745-00690-15-3CG-200745-007936221-72-6CG-200745-008936221-69-1CG-200745-009109-55-7CG-200745-010936222-18-3CG-200745-011936222-19-4CG-200745-0126723-30-4CG-200745-013936222-20-7API · ivaltinostat
CodeCAS No.Intermediate
CG-200745-001502-44-3oxepan-2-one
CG-200745-0024547-43-7methyl 6-hydroxyhexanoate
CG-200745-0036654-36-0methyl 6-oxohexanoate
CG-200745-004936221-70-41-(tert-butyl) 8-methyl 3-hydroxy-2-methyleneoctanedioate
CG-200745-005936221-71-51-(tert-butyl) 8-methyl (Z)-2-(bromomethyl)oct-2-enedioate
CG-200745-00690-15-3naphthalen-1-ol
CG-200745-007936221-72-61-(tert-butyl) 8-methyl (E)-2-((naphthalen-1-yloxy)methyl)oct-2-enedioate
CG-200745-008936221-69-1(E)-8-methoxy-2-((naphthalen-1-yloxy)methyl)-8-oxooct-2-enoic acid
CG-200745-009109-55-7N1,N1-dimethylpropane-1,3-diamine
CG-200745-010936222-18-3methyl (E)-8-((3-(dimethylamino)propyl)amino)-7-((naphthalen-1-yloxy)methyl)-8-oxooct-6-enoate
CG-200745-011936222-19-4(E)-8-((3-(dimethylamino)propyl)amino)-7-((naphthalen-1-yloxy)methyl)-8-oxooct-6-enoic acid
CG-200745-0126723-30-4O-(tetrahydro-2H-pyran-2-yl)hydroxylamine
CG-200745-013936222-20-7(E)-N1-(3-(dimethylamino)propyl)-2-((naphthalen-1-yloxy)methyl)-N8-((tetrahydro-2H-pyran-2-yl)oxy)oct-2-enediamide

Frequently asked questions

What are the approved indications of ivaltinostat?

Approved indications include: Pancreatic cancer, Myelodysplastic syndrome, Solid tumour, Fibrosis, Haematological malignancy.

When does the ivaltinostat patent expire?

No public expiry year is available for ivaltinostat yet; this page updates once verified.

How many synthesis routes are recorded for ivaltinostat?

1 synthesis routes are recorded; the shortest is 10 steps with 142 mg (CG-200745) total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy ivaltinostat intermediates?

All intermediates in ivaltinostat routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.

How do I get a quote for ivaltinostat intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-10